Literature DB >> 7618644

Clinical significance of the serial measurement of autoantibodies to neutrophil cytoplasm using a standard indirect immunofluorescence test.

A Davenport1, R J Lock, T Wallington.   

Abstract

Previous reports have suggested a relationship between changes in indirect immunofluorescence antineutrophil cytoplasm autoantibody (ANCA) titres and disease activity in patients with Wegener's granulomatosis (WG). We analyzed retrospectively the data from 37 patients with biopsy-proven WG during a median follow-up period of 34 (range 8-60) months, during which 532 serial ANCA measurements had been made. A fourfold increase in ANCA titre and/or a positive titre following a series of negative results occurred on 82 occasions, only 19 (23%) associated with clinical relapse, 25 (31%) with intercurrent infection, and 32 (38%) when patients were considered clinically well. The sensitivity of a significant increase in ANCA titre associated with clinical relapse was 43%, with a positive predictive accuracy of 23%. The combination of an increased C-reactive protein-plasma viscosity and a significant increase in ANCA titre occurred on 37 occasions, 15 (40%) with relapse and 17 (46%) with infection. The results of this study suggest that patients with WG who have significant increases in ANCA titres should be carefully monitored. Increased immunosuppression based solely on increased ANCA titres is not justified, as if this had been practiced in this study, then a large number of patients who had infective episodes would have received additional immunosuppression from which they may not have benefited.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618644     DOI: 10.1159/000168833

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  9 in total

1.  Value of ANCA measurements during remission to predict a relapse of ANCA-associated vasculitis--a meta-analysis.

Authors:  Gunnar Tomasson; Peter C Grayson; Alfred D Mahr; Michael Lavalley; Peter A Merkel
Journal:  Rheumatology (Oxford)       Date:  2011-10-29       Impact factor: 7.580

Review 2.  The clinical utility of ANCA positivity.

Authors:  J D Edgar
Journal:  Ann Rheum Dis       Date:  1996-08       Impact factor: 19.103

Review 3.  Pulmonary vasculitis: classification, clinical features, and management.

Authors:  A Ciaccia; M Ferrari; F M Facchini; G Caramori; L Fabbri
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

Review 4.  Biomarkers in ANCA-Associated Vasculitis: Potential Pitfalls and Future Prospects.

Authors:  Adam D Morris; Anthony W Rowbottom; Francis L Martin; Alexander Woywodt; Ajay P Dhaygude
Journal:  Kidney360       Date:  2021-01-19

5.  Diagnostic accuracy of antineutrophil cytoplasmic antibodies (ANCA) in predicting relapses of ANCA-associated vasculitis: systematic review and meta-analysis.

Authors:  Pankti Mehta; Anu Balakrishnan; Sanat Phatak; Mona Pathak; Sakir Ahmed
Journal:  Rheumatol Int       Date:  2022-08-30       Impact factor: 3.580

6.  Monitoring proteinase 3 antineutrophil cytoplasmic antibodies for detection of relapses in small vessel vasculitis.

Authors:  Mårten Segelmark; Brian D Phillips; Susan L Hogan; Ronald J Falk; J Charles Jennette
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

7.  Clinical spectrum associated with positive ANCA titres in 94 consecutive patients: is there a relation with PR-3 negative c-ANCA and hypergammaglobulinaemia?

Authors:  D Blockmans; E Stevens; G Mariën; H Bobbaers
Journal:  Ann Rheum Dis       Date:  1998-03       Impact factor: 19.103

8.  IgA- and SIgA anti-PR3 antibodies in serum versus organ involvement and disease activity in PR3-ANCA-associated vasculitis.

Authors:  C Sandin; P Eriksson; M Segelmark; T Skogh; A Kastbom
Journal:  Clin Exp Immunol       Date:  2016-02-25       Impact factor: 4.330

9.  Relapse rate and renal prognosis in ANCA-associated vasculitis according to long-term ANCA patterns.

Authors:  J Oristrell; J Loureiro-Amigo; R Solans; M P Valenzuela; V Monsálvez; A Segarra; M J Amengual; A Marín; C Feijoo; C Tolosa
Journal:  Clin Exp Immunol       Date:  2020-11-02       Impact factor: 4.330

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.